Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
The Imagion Biosystems (ASX:IBX) share price just exploded by 60%. Here's why
The Imagion Biosystems (ASX:IBX) share price leapt 40% in 2 days this week. What's happening?
Imagion Biosystems (ASX:IBX) share price soars 13% on quarterly update
Imagion (ASX:IBX) share price zips 38% higher. Here's why
Imagion (ASX:IBX) share price up 1,166% in a year pursuing 'radiation-free' cancer tech
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.
|08 Dec 2023||$0.40||$-0.01||-2.47%||89,929||$0.41||$0.43||$0.39|
|07 Dec 2023||$0.41||$0.06||17.39%||438,761||$0.40||$0.43||$0.35|
|06 Dec 2023||$0.35||$0.02||6.15%||34,025||$0.33||$0.36||$0.33|
|05 Dec 2023||$0.33||$-0.02||-5.80%||18,862||$0.34||$0.36||$0.33|
|04 Dec 2023||$0.35||$-0.03||-8.11%||30,932||$0.37||$0.37||$0.33|
|01 Dec 2023||$0.37||$0.02||5.71%||37,204||$0.38||$0.39||$0.36|
|30 Nov 2023||$0.35||$0.01||2.94%||26,188||$0.34||$0.39||$0.34|
|29 Nov 2023||$0.34||$0.02||6.25%||26,000||$0.34||$0.35||$0.33|
|28 Nov 2023||$0.32||$-0.02||-5.97%||29,076||$0.34||$0.35||$0.32|
|27 Nov 2023||$0.34||$-0.11||-25.00%||12,516||$0.34||$0.34||$0.32|
|15 Nov 2023||$0.44||$0.04||10.00%||2,487,990||$0.44||$0.44||$0.42|
|14 Nov 2023||$0.40||$-0.08||-16.67%||2,739,465||$0.44||$0.44||$0.40|
|13 Nov 2023||$0.48||$0.08||20.00%||2,340,771||$0.44||$0.48||$0.42|
|10 Nov 2023||$0.40||$-0.04||-9.09%||7,836,973||$0.48||$0.48||$0.40|
|09 Nov 2023||$0.44||$-0.04||-8.33%||1,103,159||$0.48||$0.48||$0.44|
|28 Apr 2023||Michael (Mike) Harsh||Expiry||60,000||$900||
As advised by the company.
|28 Apr 2023||Mark Van Asten||Expiry||120,000||$1,800||
|28 Apr 2023||David Ludvigson||Expiry||120,000||$1,800||
|28 Apr 2023||Robert Proulx||Expiry||282,000||$4,230||
|28 Apr 2023||Jovanka Naumoska||Expiry||60,000||$900||
|21 Apr 2023||Dianne Angus||Issued||30,375||$516||
|21 Apr 2023||Dianne Angus||Issued||50,000||$850||
As advised by the company. Shortfall
|21 Apr 2023||Mark Van Asten||Issued||68,125||$1,158||
|21 Apr 2023||Jovanka Naumoska||Issued||32,500||$552||
|Ms Dianne Margaret Angus||Non-Executive Director||May 2020||
Ms Angus has worked as a senior executive within the biotechnology, medtech, agritech and healthcare sectors for over twenty years and currently serves as non-executive director with Neuren Pharmaceuticals Limited, Cyclopharm Limited and Bionic Vision Technologies Limited as well as being a member of the Deakin University Council. She has built competitive and differentiated product portfolios, from investment in innovative research and product development to commercialisation and market entry. She is also a member of Disclosure Committee.
|Mr Michael (Mike) John Harsh||Non-Executive Director||Feb 2017||
Mr Harsh is a co-founder and Chief Product Officer of Terapede Systems, a digital X-ray startup that focuses on developing an ultra-high resolution medical flat panel X-ray detector. Prior to co-founding Terapede Systems in 2015, Mr. Harsh had a 36-year long career with General Electric, including serving as Global Technology Leader Imaging Technologies at the GE Global Research Center and culminating with him serving as Vice President and Chief Technology of GE Healthcare. He had previously served as a director for FloDesign Sonics until its acquisition by MilliporeSigma, a division of the Merck Group. He is member of Risk Committee.
|Mr Mark Gerald Van Asten||Non-Executive Director||Dec 2016||
Mr Asten has over 30 years of experience in the medical diagnostics and life sciences industry. Much of this time has been in international business development, strategic planning, and introduction of new technology. Through Diagnostic Technology, a company he founded, he has been responsible for the development and introduction of several innovative technology platforms and technologies into mainstream healthcare use, including HPV DNA testing for cervical cancer screening and the molecular monitoring for both viral infections and cancer treatments. He is also a member of Risk Committee.
|Mr David Gerald Ludvigson||Non-Executive Director||Mar 2017||
Mr Ludvigson is currently a director (was formerly President and CEO) af Nanomix, a point-of-care diagnostic medical device company. David is a financial and operating executive with over 35 years of international experience in life sciences and technology companies including Biogen (formerly IDEC Pharmaceuticals), Matrix Pharmaceutical, Nanogen, and MIPS Computer Systems. His experience over 15 years in the diagnostics arena has led numerous new product efforts from concept to market launch. David has conducted many strategic transactions including multiple acquisitions, corporate partnerships, technology and intellectual property licensing agreements, and OEM relationships and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources. He is also a member of Risk and Disclosure Committee.
|Mr Robert Romeo Proulx||Executive ChairmanExecutive Director||Dec 2016||
Mr Proulx has been CEO and President of Imagion Biosystems since February 2015. Previous employment experience includes President / General Manager for Silicon Biosystems and a career in marketing and sales management with more than 25 years experience in the computer, life science and medical diagnostics industries. Some of Robert's other relevant experience includes Vice President Marketing and Sales for Nanogen Inc.; Senior Vice President of Marketing and Business Development at Gene Logic; and General Manager, Life Sciences at IGEN International Inc.
|Ms Jovanka Naumoska||Non-Executive Director||Dec 2016||
Ms Naumoska is an Australian-qualified corporate lawyer with experience in legal and regulatory issues pertaining to medical imaging technology. Jovanka is currently a nonexecutive director of Security Matters Limited and serves Australian scientific development organisations in an expert capacity on matters relating to corporate law, business operations, intellectual property development and regulatory compliance. She is also a member of Disclosure Committee.
|Dr Isaac Bright||Chief Executive OfficerManaging Director||Jun 2023||
Dr Bright most recently served as Co-Founder, CEO, and Chairman of RubrYc Therapeutics, Inc. before its trade sale to iBio, Inc. (NYSEA: IBIO) in September 2022. Prior to launching Rubric, Dr Bright was Chief Business Officer for molecular diagnostics innovator Health Tell, Inc., driving its trade sale to iCarbonX, concomitant with RubrYcs launch in 2018. Prior to that, Dr. Bright served as VP, Corporate Development for Synthetic Biologics, Inc. and consoling Chief Business Officer for synthetic biology innovator musebio, Inc. (currently Incripta, Inc.)Dr Bright was the first American Partner investing with Merieux Developpement (currently, Merieux Equity Partners) from 2012 through 2016. With Merieux, Dr Bright led investments and Board representation for Imaginab, Inc., Kalila Medical, Inc. its acquisition by Abbo (NYSE: ABT), and Twist Bioscience before its IPO (NASDAQ: TWST). Dr Brights startup experience began as he built and led QuantaLife, Inc.s Corporate Development and Molecular Diagnostics functions from 2009-2011, leading to QuantaLifes acquisition by Bio-Rad Laboratories, Inc. (NYSE: BIO). Previously, Dr Bright served as Sr. Associate, Corporate Development and Director, Business Development - Neuromodulation for global medtech leader Medtronic (NYSE: MDT).
|Mr Geoff Hollis||Chief Financial OfficerCompany Secretary||Dec 2020||
|Yalia Jayalakshmi||Chief Development Officer||
|Geoff Hollis||Chief Financial OfficerCompany Secretary||
|HSBC Custody Nominees (Australia) Limited||56,178,508||5.01%|
|Citicorp Nominees Pty Limited||27,944,616||2.49%|
|BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>||11,369,662||1.01%|
|Mr Haojie Li||11,000,000||0.98%|
|The Board Of Regents Of The University Of Texas System||10,529,053||0.94%|
|BNP Paribas Noms Pty Ltd <Drp>||10,310,929||0.92%|
|Mr Yusuf Kucukbas <Yasep A/C>||9,999,990||0.89%|
|E & W Nominee Pty Ltd <Liang Family Super Fund A/C>||9,609,498||0.86%|
|Mr Anestis Lazaridis||8,830,703||0.79%|
|Wh & Pr Pty Ltd <Robhoo Unit A/C>||8,000,000||0.71%|
|G & D Finn Pty Ltd||7,000,000||0.62%|
|Mr Feeras Najjar <Najjar Family A/C>||6,750,000||0.60%|
|Mr Gj Howlett & Mrs Mw Howlett <Gh Super Fund A/C>||6,740,000||0.60%|
|Mr Robert Proulx||6,163,250||0.55%|
|Mr Yoanto Wakimin||5,594,681||0.50%|
|HSBC Custody Nominees (Australia) Limited i||5,401,069||0.48%|
|HSBC Custody Nominees (Australia) Limited A/C 2||5,161,262||0.46%|
|Azzams Trading Pty Ltd||5,000,000||0.45%|
|Bairdos Pty Ltd||5,000,000||0.45%|
|Dr Russell Kay Hancock||4,000,000||0.36%|